Dillman R O
Crit Rev Oncol Hematol. 1984;1(4):357-85. doi: 10.1016/s1040-8428(84)80008-6.
Potential uses of monoclonal antibodies in anti-cancer treatment include passive serotherapy, radioisotope conjugates, toxin-linked conjugates, and chemotherapy-monoclonal antibody conjugates. The bases for these applications have been founded in research with heterologous antisera, and in some cases with monoclonal antibodies in animal tumor models. Human trials with passive serotherapy have already begun in both hematopoietic and solid tumor malignancies. Promising results have been reported in cutaneous T cell lymphoma with anti-T cell monoclonal antibody, and in nodular lymphoma with anti-idiotype monoclonal antibody. Radioisotope conjugate work appears promising for imaging in both animals and humans, and this work will lay the foundation for possible therapeutic application of radio-immunotherapy. Toxin-linked conjugates are promising in vitro and may have application in autologous bone marrow transplantation. Research with chemotherapy conjugates is also underway. Preliminary results suggest that murine monoclonal antibodies will be well tolerated clinically except in the setting of circulating cells which bear the target antigen, where rapid infusions may be associated with intolerable side effects. In certain diseases, production of endogenous anti-mouse antibodies may also limit application. Advances in the technology for human-human hybridoma production may help solve some of these problems.
单克隆抗体在抗癌治疗中的潜在用途包括被动血清疗法、放射性同位素偶联物、毒素连接偶联物和化疗-单克隆抗体偶联物。这些应用的基础建立在对异种抗血清的研究上，在某些情况下也建立在动物肿瘤模型中对单克隆抗体的研究上。被动血清疗法的人体试验已经在造血系统恶性肿瘤和实体瘤中展开。在皮肤T细胞淋巴瘤中使用抗T细胞单克隆抗体以及在结节性淋巴瘤中使用抗独特型单克隆抗体均已报道了有前景的结果。放射性同位素偶联物在动物和人体成像方面似乎很有前景，这项工作将为放射免疫治疗的可能治疗应用奠定基础。毒素连接偶联物在体外很有前景，可能应用于自体骨髓移植。化疗偶联物的研究也在进行中。初步结果表明，除了在携带靶抗原的循环细胞情况下，鼠单克隆抗体在临床上耐受性良好，在这种情况下快速输注可能会伴有无法耐受的副作用。在某些疾病中，内源性抗鼠抗体的产生也可能限制应用。人-人杂交瘤生产技术的进步可能有助于解决其中一些问题。
